Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors? (CROSBI ID 312014)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Roguljić, Hrvoje ; Arambašić, Jerko ; Ninčević, Vjera ; Kuna, Lucija ; Šesto Igor ; Tabll, Ashraf ; Smolić, Robert ; Včev, Aleksandar ; Primorac, Dragan ; Wu, George et al. The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors? // Croatian medical journal, 63 (2022), 287-294

Podaci o odgovornosti

Roguljić, Hrvoje ; Arambašić, Jerko ; Ninčević, Vjera ; Kuna, Lucija ; Šesto Igor ; Tabll, Ashraf ; Smolić, Robert ; Včev, Aleksandar ; Primorac, Dragan ; Wu, George ; Smolić, Martina

engleski

The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?

In patients with COVID-19, thromboinflammation is one of the main causes of morbidity and mortality, which makes anticoagulation an integral part of treatment. However, pharmacodynamic and pharmacokinetic properties of direct oral anticoagulants (DOACs) limit the use of this class of anticoagulants in COVID-19 patients due to a significant interference with antiviral agents. DOACs use in COVID-19 hospitalized patients is currently not recommended. Furthermore, patients already on oral anticoagulant drugs should be switched to heparin at hospital admission. Nevertheless, outpatients with a confirmed diagnosis of COVID-19 are recommended to continue prior DOAC therapy. More studies are required to clarify the pathogenesis of COVID-19-induced derangement of the coagulation system in order to recommend an appropriate anticoagulant treatment.

direct oral anticoagulants, COVID-19, antiviral therapy, pharmacogenetic

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

63

2022.

287-294

objavljeno

0353-9504

1332-8166

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost